Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARNANASDAQ:CCXINASDAQ:FTSVNASDAQ:INSM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARNAArena Pharmaceuticals$99.99$97.65$45.50▼$100.00$6.17B0.551.56 million shs107 shsCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AINSMInsmed$97.62-3.0%$79.16$60.40▼$106.83$19.09B0.92.31 million shs3.83 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARNAArena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%INSMInsmed+1.16%-4.53%+43.83%+39.78%+50.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARNAArena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed4.1122 of 5 stars2.54.00.04.33.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARNAArena Pharmaceuticals 0.00N/AN/AN/ACCXIChemoCentryx 0.00N/AN/AN/AFTSVForty Seven 0.00N/AN/AN/AINSMInsmed 3.00Buy$106.809.40% UpsideCurrent Analyst Ratings BreakdownLatest INSM, ARNA, FTSV, and CCXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.006/11/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.006/11/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.006/11/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.006/11/2025INSMInsmedBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$94.00 ➝ $109.006/11/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$90.00 ➝ $120.006/10/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/10/2025INSMInsmedCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy6/10/2025INSMInsmedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARNAArena Pharmaceuticals$50K123,305.67N/AN/A$10.94 per share9.14CCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70INSMInsmed$363.71M50.92N/AN/A$1.60 per share61.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARNAArena Pharmaceuticals-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/ACCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AINSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)Latest INSM, ARNA, FTSV, and CCXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARNAArena PharmaceuticalsN/AN/AN/AN/AN/ACCXIChemoCentryxN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARNAArena Pharmaceuticals0.058.598.59CCXIChemoCentryx0.024.544.47FTSVForty SevenN/A14.8114.81INSMInsmed11.385.865.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARNAArena Pharmaceuticals83.77%CCXIChemoCentryx81.09%FTSVForty Seven71.77%INSMInsmedN/AInsider OwnershipCompanyInsider OwnershipARNAArena Pharmaceuticals2.41%CCXIChemoCentryx8.30%FTSVForty Seven37.40%INSMInsmed3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARNAArena Pharmaceuticals44861.66 million60.17 millionOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableFTSVForty Seven5748.16 millionN/ANot OptionableINSMInsmed1,271189.71 million184.02 millionOptionableINSM, ARNA, FTSV, and CCXI HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Has $31.59 Million Stock Holdings in Insmed, Inc. (NASDAQ:INSM)July 1 at 4:48 AM | marketbeat.comInsmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by BrokeragesJuly 1 at 2:47 AM | marketbeat.comPeregrine Capital Management LLC Sells 12,486 Shares of Insmed, Inc. (NASDAQ:INSM)June 30 at 8:32 AM | marketbeat.comOppenheimer Asset Management Inc. Has $1.52 Million Holdings in Insmed, Inc. (NASDAQ:INSM)June 28 at 3:38 AM | marketbeat.comHere’s how Insmed grows to be the next $100 billion biotechJune 26, 2025 | statnews.comSInsmed, Inc. (NASDAQ:INSM) CFO Sells $5,879,321.70 in StockJune 25, 2025 | marketbeat.comInsmed, Inc. (NASDAQ:INSM) Position Decreased by Fourth Dimension Wealth LLCJune 24, 2025 | marketbeat.comYorktown Management & Research Co Inc Reduces Holdings in Insmed, Inc. (NASDAQ:INSM)June 24, 2025 | marketbeat.comInsmed (NASDAQ:INSM) Reaches New 12-Month High - Still a Buy?June 23, 2025 | marketbeat.comWhalen Wealth Management Inc. Invests $217,000 in Insmed, Inc. (NASDAQ:INSM)June 23, 2025 | marketbeat.comSowell Financial Services LLC Makes New $255,000 Investment in Insmed, Inc. (NASDAQ:INSM)June 22, 2025 | marketbeat.comWhat Makes Insmed Incorporated (INSM) an Investment Bet?June 20, 2025 | insidermonkey.comRussell Rebalance: 3 Stocks Ready to Move Higher (INSM)...June 20, 2025 | marketbeat.com6INSM : What Does the Market Think About Insmed?June 20, 2025 | benzinga.comWilliam Lewis Sells 129,805 Shares of Insmed, Inc. (NASDAQ:INSM) StockJune 19, 2025 | insidertrades.comMizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110June 18, 2025 | msn.comInsmed, Inc. (NASDAQ:INSM) CEO Sells $13,031,123.95 in StockJune 18, 2025 | marketbeat.comWells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107June 17, 2025 | msn.comAssenagon Asset Management S.A. Has $3.04 Million Holdings in Insmed Incorporated (NASDAQ:INSM)June 17, 2025 | marketbeat.comInsmed (NASDAQ:INSM) Reaches New 12-Month High - Should You Buy?June 16, 2025 | marketbeat.comIs Insmed Stock Overvalued After The 45% Jump?June 16, 2025 | forbes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherINSM, ARNA, FTSV, and CCXI Company DescriptionsArena Pharmaceuticals NASDAQ:ARNAArena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.ChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Forty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Insmed NASDAQ:INSM$97.62 -3.02 (-3.00%) Closing price 04:00 PM EasternExtended Trading$97.12 -0.50 (-0.52%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
